Advances in the development of site-specific antibody-drug conjugation

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 7, 2015, Pages 828-836

  Zhou, Qun ^a   Kim, Jennifer ^a  

^a SANOFI   (France)

Author keywords

Antibody drug conjugate; Conjugation through unnatural amino acids or amino acid derivatives; Cysteine conjugation; Glutamine conjugation; Glycoconjugation; Lysine conjugation; Site specific conjugation

Indexed keywords

CARBOHYDRATE; CEMADOTIN; CYSTEINE; GLUTAMINE; IMMUNOGLOBULIN G; IODOACETAMIDE; LYSINE; MALEIMIDE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRASTUZUMAB; ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT;

ALKYLATION; ANTIBODY DRUG CONJUGATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CROSS LINKING; CYTOTOXICITY; DISULFIDE BOND; DRUG CONJUGATION; DRUG STABILITY; ANIMAL; CHEMISTRY; HUMAN;

ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARBOHYDRATES; CYSTEINE; GLUTAMINE; HUMANS; IMMUNOCONJUGATES;

EID: 84938679600     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150302125448     Document Type: Article

References (70)

1. Ho, R.J.; Chien, J. Trends in translational medicine and drug targeting and delivery: New insights on an old concept-targeted drug delivery with antibody-drug conjugates for cancers. J. Pharm. Sci., 2014, 103, 71-77.
2. Panowski, S.; Bhakta, S.; Raab, H.; Polakis, P.; Junutula, J.R. Sitespecific antibody drug conjugates for cancer therapy. MABS., 2014, 6, 12.
3. Yang, H.M.; and Reisfeld, R.A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA, 1988, 85, 1189-1193.
4. Elias, D.J.; Hirschowitz, L.; Kline, L.E.; Kroener, J.F.; Dillman, R. O.; Walker, L.E.; Robb, J.A. Timms, R.M. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4- methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res., 1990, 50, 4154-4159.
5. Saleh, M.N.; Sugarman, S.; Murray, J.; Ostroff, J.B.; Healey, D.; Jones, D.; Daniel, C.R.; LeBherz, D.; Brewer, H.; Onetto, N.; LoBuglio, A.F. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Yexpressing epithelial tumors. J. Clin. Oncol., 2000, 18, 2282-2292.
6. Doronina, S.O.; Toki, B.E.; Torgov, M.Y.; Mendelsohn, B.A.; Cerveny, C.G.; Chace, D.F.; DeBlanc, R. L.; Gearing, R.P.; Bovee, T.D.; Siegall, C.B.; Francisco, J.A.; Wahl, A.F.; Meyer, D.L.; Senter, P.D. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol., 2013, 21, 778-784.
7. Senter, P.D.; and Sievers, E.L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol., 2012, 30, 631-637.
8. Erickson, H.K.; Lewis Phillips, G.D.; Leipold, D.D.; Provenzano, C.A.; Mai, E.; Johnson, H.A.; Gunter, B.; Audette, C.A.; Gupta, M.; Pinkas, J.; Tibbitts, J. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol. Cancer Ther., 2012, 11, 1133-1142.
9. Gualberto, A. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Exp. Opin. Investig. Drugs, 2012, 21, 205-216.
10. Haddley, K. Brentuximab vedotin: Its role in the treatment of anaplastic large cell and Hodgkin's lymphoma. Drugs Today (Barc), 2012, 48, 259-270.
11. Siddiqi, T.; Thomas, S.H.; Chen, R. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. Pharmgenom. Pers. Med., 2014, 7, 79-85.
12. Horwitz, S.M.; Advani, R.H.; Bartlett, N.L.; Jacobsen, E.D.; Sharman, J.P.; O'Connor, O.A.; Siddiqi, T.; Kennedy, D.A.; Oki, Y. Objective responses in relapsed T-cell lymphomas with single agent brentuximab vedotin. Blood, 2014, 123(20), 3095-3100.
13. Perini, G.F.; Pro, B. Brentuximab Vedotin in CD30+ Lymphomas. Biol Ther, 2013, 3, 15-23.
14. LoRusso, P.M.; Weiss, D.; Guardino, E.; Girish, S.; Sliwkowski, M.X. Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2- positive cancer. Clin. Cancer Res., 2011, 17, 6437-6447.
15. Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr. Opin. Mol. Ther., 2010, 12, 350-360.
16. Krop, I.E.; Kim, S.B.; Gonzalez-Martin, A.; Lorusso, P.M.; Ferrero, J.M.; Smitt, M.; Yu, R.; Leung, A.C.; Wildiers, H. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial. Lancet Oncol., 2014, 15(7), 689-699.
17. Dhillon, S. Trastuzumab Emtansine: A review of its use in patients with her2-positive advanced breast cancer previously treated with trastuzumab-based therapy. Drugs, 2014, 74(6), 675-686.
18. Krop, I.; Winer, E.P. Trastuzumab emtansine: A novel antibodydrug conjugate for HER2-positive breast cancer. Clin. Cancer Res., 2014, 20, 15-20.
19. Alley, S.C.; Okeley, N.M.; Senter, P.D. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr. Opin. Chem. Biol., 2010, 14, 529-537.
20. Carter, P.J.; Senter, P.D. Antibody-drug conjugates for cancer therapy. Cancer J., 2008, 14, 154-169.
21. Casi, G.; Neri, D. Antibody-drug conjugates: Basic concepts, examples, and future perspectives. J. Cont. Rel., 2012, 161, 167.
22. Ducry, L.; Stump, B. Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem., 2010, 21, 5-13.
23. Firer, M. Antibody-drug conjugates in cancer therapy-filling in the potholes that lie ahead. OA Cancer, 2013, 19, 6.
24. Lambert, J.M. Drug-conjugated antibodies for the treatment of cancer. Bri. J. Clin. Pharmacol., 2012, 76, 5.
25. Teicher, B.A. Antibody-drug conjugate targets. Curr. Cancer Drug Targ., 2009, 9, 982-1004.
26. Beck, A. Review of Antibody-Drug Conjugates, Methods in molecular biology series: A book edited by Laurent Ducry. MABS, 2014, 6, 30-33.
27. Anderl, J.; Faulstich, H.; Hechler, T.; Kulke, M. Antibody-drug conjugate payloads. Methods Mol. Biol., 2013, 1045, 51-70.
28. Bander, N.H. Antibody-drug conjugate target selection: Critical factors. Methods Mol. Biol., 2013, 1045, 29-40.
29. Sassoon, I.; Blanc, V. Antibody-drug conjugate (ADC) clinical pipeline: A review. Methods Mol. Biol., 2013, 1045, 1-27.
30. Gerber, H.P.; Koehn, F.E.; Abraham, R.T. The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep., 2013, 30, 625-639.
31. Flygare, J.A.; Pillow, T.H.; Aristoff, P. Antibody-drug conjugates for the treatment of cancer. Chem. Biol. Drug Des., 2013, 81, 113-121.
32. Sievers, E.L.; Senter, P.D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med., 2013, 64, 15-29.
33. Okeley, N.M.; Alley, S.C.; Senter, P.D. Advancing antibody drug conjugation: From the laboratory to a clinically approved anticancer drug. Hematol. Oncol. Clin. North Am., 2014, 28, 13-25.
34. Behrens, C.R.; Liu, B. Methods for site-specific drug conjugation to antibodies. MABS, 2014, 6, 8.
35. Lobo, E.D.; Hansen, R.J.; Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci., 2004, 93, 2645-2668.
36. Hamblett, K.J.; Senter, P.D.; Chace, D.F.; Sun, M.M.; Lenox, J.; Cerveny, C.G.; Kissler, K.M.; Bernhardt, S.X.; Kopcha, A.K.; Zabinski, R.F.; Meyer, D.L.; Francisco, J. A. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res., 2004, 10, 7063-7070.
37. Junutula, J.R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D.D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S.P.; Dennis, M.S.; Lu, Y.; Meng, Y.G.; Ng, C.; Yang, J.; Lee, C.C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S.D.; Lee Wong, W.; Lowman, H.B.; Vandlen, R.; Sliwkowski, M.X.; Scheller, R.H.; Polakis, P.; Mallet, W. Sitespecific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol., 2008, 26, 925-932.
38. Shen, B.Q.; Xu, K.; Liu, L.; Raab, H.; Bhakta, S.; Kenrick, M.; Parsons-Reponte, K.L.; Tien, J.; Yu, S.F.; Mai, E.; Li, D.; Tibbitts, J.; Baudys, J.; Saad, O.M.; Scales, S.J.; McDonald, P.J.; Hass, P. E.; Eigenbrot, C.; Nguyen, T.; Solis, W. A.; Fuji, R.N.; Flagella, K. M.; Patel, D.; Spencer, S.D.; Khawli, L.A.; Ebens, A.; Wong, W. L.; Vandlen, R.; Kaur, S.; Sliwkowski, M.X.; Scheller, R.H.; Polakis, P.; Junutula, J.R. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol., 2012, 30, 184-189.
39. Alley, S.C.; Benjamin, D.R.; Jeffrey, S.C.; Okeley, N.M.; Meyer, D.L.; Sanderson, R.J.; Senter, P.D. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug. Chem., 2008, 19, 759-765.
40. Wang, L.; Amphlett, G.; Blattler, W.A.; Lambert, J.M.; Zhang, W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci., 2005, 14, 2436-2446.
41. Fleming, M.S.; Zhang, W.; Lambert, J.M.; Amphlett, G. A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. Anal. Biochem., 2005, 340, 272-278.
42. Stephan, J.P.; Kozak, K.R.; Wong, W.L. Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates. Bioanalysis, 2011, 3, 677-700.
43. Chih, H.W.; Gikanga, B.; Yang, Y.; Zhang, B. Identification of amino acid residues responsible for the release of free drug from an antibody-drug conjugate utilizing lysine-succinimidyl ester chemistry. J. Pharm. Sci., 2011, 100, 2518-2525.
44. Junutula, J.R.; Flagella, K.M.; Graham, R.A.; Parsons, K.L.; Ha, E.; Raab, H.; Bhakta, S.; Nguyen, T.; Dugger, D.L.; Li, G.; Mai, E.; Lewis Phillips, G.D.; Hiraragi, H.; Fuji, R.N.; Tibbitts, J.; Vandlen, R.; Spencer, S.D.; Scheller, R.H.; Polakis, P. Sliwkowski, M.X. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin. Cancer Res., 2010, 16, 4769-4778.
45. Jeffrey, S.C.; Burke, P.J.; Lyon, R.P.; Meyer, D.W.; Sussman, D.; Anderson, M.; Hunter, J.H.; Leiske, C.I.; Miyamoto, J.B.; Nicholas, N.D.; Okeley, N.M.; Sanderson, R.J.; Stone, I.J.; Zeng, W.; Gregson, S.J.; Masterson, L.; Tiberghien, A.C.; Howard, P.W.; Thurston, D.E.; Law, C.L.; and Senter, P.D. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug. Chem., 2013, 24, 1256-1263.
46. Klinguer-Hamour, C.; Strop, P.; Shah, D.K.; Ducry, L.; Xu, A.; Beck, A. World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MABS, 2014, 6, 18-29.
47. Casi, G.; Huguenin-Dezot, N.; Zuberbuhler, K.; Scheuermann, J.; Neri, D. Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J. Am. Chem. Soc., 2012, 134, 5887-5892.
48. Strop, P.; Liu, S.H.; Dorywalska, M.; Delaria, K.; Dushin, R.G.; Tran, T.T.; Ho, W.H.; Farias, S.; Casas, M.G.; Abdiche, Y.; Zhou, D.; Chandrasekaran, R.; Samain, C.; Loo, C.; Rossi, A.; Rickert, M.; Krimm, S.; Wong, T.; Chin, S.M.; Yu, J.; Dilley, J.; Chaparro- Riggers, J.; Filzen, G.F.; O'Donnell, C.J.; Wang, F.; Myers, J.S.; Pons, J.; Shelton, D.L.;and Rajpal, A. Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol., 2013, 20, 161-167.
49. Dennler, P.; Chiotellis, A.; Fischer, E.; Bregeon, D.; Belmant, C.; Gauthier, L.; Lhospice, F.; Romagne, F.; Schibli, R. Transglutaminasebased chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug. Chem., 2014, 25, 569-578.
50. Mimura, Y.; Sondermann, P.; Ghirlando, R.; Lund, J.; Young, S. P.; Goodall, M.; Jefferis, R. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J. Biol. Chem., 2001, 276, 45539-45547.
51. Jefferis, R. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci., 2009, 30, 356-362.
52. Hinman, L.M.; Hamann, P.R.; Wallace, R.; Menendez, A.T.; Durr, F. E.; Upeslacis, J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Res., 1993, 53, 3336-3342.
53. Hamann, P.R.; Hinman, L.M.; Beyer, C.F.; Greenberger, L.M.; Lin, C.; Lindh, D.; Menendez, A.T.; Wallace, R.; Durr, F.E.; Upeslacis, J. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug. Chem., 2005, 16, 346-353.
54. Zuberbuhler, K.; Casi, G.; Bernardes, G.J.L.; Neri, D. Fucosespecific conjugation of hydrazide derivatives to a vasculartargeting monoclonal antibody in IgG format. Chem. Commun., 2012, 48(56) 7100-7102.
55. Zhou, Q.; Stefano, J.E.; Manning, C.; Kyazike, J.; Chen, B.; Gianolio, D.A.; Park, A.; Busch, M.; Bird, J.; Zheng, X.; Simonds- Mannes, H.; Kim, J.; Gregory, R.C.; Miller, R.J.; Brondyk, W.H.; Dhal, P.K.; Pan, C.Q. Site-specific antibody-drug conjugation through glycoengineering. Bioconjug. Chem., 2014, 25, 510-520.
56. Okeley, N.M.; Toki, B.E.; Zhang, X.; Jeffrey, S.C.; Burke, P.J; Alley, S.C.; Senter, P.D. Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation. Bioconjug. Chem., 2013, 24, 1650-1655.
57. Boeggeman, E.; Ramakrishnan, B.; Pasek, M.; Manzoni, M.; Puri, A.; Loomis, K.H.; Waybright, T.J.; Qasba, P.K. Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: Application for cell surface antigen detection. Bioconjug. Chem., 2009, 20, 1228-1236.
58. Ramakrishnan, B.; Boeggeman, E.; Pasek, M.; Qasba, P.K. Bioconjugation using mutant glycosyltransferases for the sitespecific labeling of biomolecules with sugars carrying chemical handles. Methods Mol. Biol., 2011, 751, 281-296.
59. Zeglis, B.M.; Davis, C.B.; Aggeler, R.; Kang, H.C.; Chen, A.; Agnew, B.J.; Lewis, J.S.(2013) Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug. Chem., 2013, 1057-1067.
60. Li, X.; Fang, T.; Boons, G.J. Preparation of well-defined antibodydrug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. Angew. Chem. Int. Ed. Engl., 2014, 53, 7179-7182.
61. Axup, J.Y.; Bajjuri, K.M.; Ritland, M.; Hutchins, B.M.; Kim, C. H.; Kazane, S.A.; Halder, R.; Forsyth, J.S.; Santidrian, A.F.; Stafin, K.; Lu, Y.; Tran, H.; Seller, A.J.; Biroc, S.L.; Szydlik, A.; Pinkstaff, J.K.; Tian, F.; Sinha, S.C. Felding-Habermann, B.; Smider, V.V.; Schultz, P.G. Synthesis of site-specific antibodydrug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA, 2012, 109, 16101-16106.
62. Rabuka, D.; Rush, J.S.; DeHart, G.W.; Wu, P.; Bertozzi, C.R. Sitespecific chemical protein conjugation using genetically encoded aldehyde tags. Nat. Protoc., 2012, 7, 1052-1067.
63. Tian, F.; Lu, Y.; Manibusan, A.; Sellers, A.; Tran, H.; Sun, Y.; Phuong, T.; Barnett, R.; Hehli, B.; Song, F.; DeGuzman, M.J.; Ensari, S.; Pinkstaff, J.K.; Sullivan, L.M.; Biroc, S.L.; Cho, H.; Schultz, P.G.; DiJoseph, J.; Dougher, M.; Ma, D.; Dushin, R.; Leal, M.; Tchistiakova, L.; Feyfant, E.; Gerber, H.P.; Sapra, P. A general approach to site-specific antibody drug conjugates. Proc. Natl. Acad. Sci. USA, 2014, 111, 1766-1771.
64. Jackson, D.; Atkinson, J.; Guevara, C.I.; Zhang, C.; Kery, V.; Moon, S.J.; Virata, C.; Yang, P.; Lowe, C.; Pinkstaff, J.; Cho, H.; Knudsen, N.; Manibusan, A.; Tian, F.; Sun, Y.; Lu, Y.; Sellers, A.; Jia, X.C.; Joseph, I.; Anand, B.; Morrison, K.; Pereira, D.S.; Stover, D. In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates. PLoS One, 2014, 9, e83865.
65. Zimmerman, E.S.; Heibeck, T.H.; Gill, A.; Li, X.; Murray, C.J.; Madlansacay, M.R.; Tran, C.; Uter, N.T.; Yin, G.; Rivers, P.J.; Yam, A.Y.; Wang, W.D.; Steiner, A.R.; Bajad, S.U.; Penta, K.; Yang, W.; Hallam, T.J.; Thanos, C.D.; Sato, A.K. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem., 2014, 25, 351-361.
66. Wu, P.; Shui, W.; Carlson, B.L.; Hu, N.; Rabuka, D.; Lee, J.; Bertozzi, C.R. Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag. Proc. Natl. Acad. Sci. USA, 2009, 106, 3000-3005.
67. Agarwal, P.; Kudirka, R.; Albers, A.E.; Barfield, R.M.; De Hart, G. W.; Drake, P.M.; Jones, L.C.; Rabuka, D. Hydrazino-Pictet- Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug. Chem., 2013, 24, 846-851.
68. Agarwal, P.; Van der Weijden, J.; Sletten, E.M.; Rabuka, D.; Bertozzi, C.R. A Pictet-Spengler ligation for protein chemical modification. Proc. Natl. Acad. Sci. USA, 2013, 110, 46-51.
69. Li, X.; Yang, J.; Rader, C. Antibody conjugation via one and two C-terminal selenocysteines. Methods, 2014, 65, 133-138.
70. Kalia, J.; Raines, R.T. Hydrolytic stability of hydrazones and oximes. Angew. Chem. Int. Ed. Engl., 2008, 47, 7523-7526.